Metastatic Synovial Sarcoma: Clinical Trials

4 trials for Metastatic Synovial Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1
Phase 12Active not recruiting 1, Terminated 1

Follow Metastatic Synovial Sarcoma: new trials by email Literature Review of Metastatic Synovial Sarcoma trials Research Report on Metastatic Synovial Sarcoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Phase 2Not yet recruitingNational Cancer Institute (NCI)422026-11-232026-09-25
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Phase 2CompletedNational Cancer Institute (NCI)282017-12-142023-10-25
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Phase 1 / Phase 2Active not recruitingRoswell Park Cancer Institute152017-07-142026-07-08
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23

Narrower conditions

Sarcoma, Synovial (4)  ·  Liposarcoma, Myxoid (2)  ·  Dermatofibrosarcoma (1)  ·  Fallopian Tube Neoplasms (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Leiomyosarcoma (1)  ·  Melanoma (1)  ·  Mycosis Fungoides (1)  ·  Neurofibrosarcoma (1)  ·  Ovarian Neoplasms (1)  ·  Sezary Syndrome (1)

Broader conditions

Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Connective Tissue (4)  ·  Neoplasms, Connective and Soft Tissue (4)  ·  Sarcoma (4)  ·  Liposarcoma (2)  ·  Neoplasms, Adipose Tissue (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Adnexal Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Fibrosarcoma (1)

Interventions

Biopsy (1)  ·  Cyclophosphamide (1)  ·  Decitabine (1)  ·  Injections (1)  ·  Interferon-gamma (1)  ·  Leukapheresis (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  interferon gamma-1b (1)  ·  pazopanib (1)  ·  pembrolizumab (1)  ·  sapanisertib (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Roswell Park Cancer Institute (1)

Countries

United States (3)

Top investigators

Michael S Khodadoust, MD (1)  ·  Michael Wagner (1)  ·  Philip McCarthy, MD (1)  ·  William D Tap (1)

Results publications

PMID 32269142

NIH funding

P30CA015704 (1), P30CA016056 (1), R01CA164333 (1), U01CA154967 (1), U10CA180821 (1), UM1CA186709 (1)